Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study

Article information

Kidney Res Clin Pract. 2017;36(1):48-57
Publication date (electronic) : 2017 March 31
doi : https://doi.org/10.23876/j.krcp.2017.36.1.48
1Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea
2Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
3Department of Policy Research Affairs, National Health Insurance Service Ilsan Hospital, Goyang, Korea
4Department of Internal Medicine, NHIS Medical Center, Ilsan Hospital, Goyang, Korea
5Brain Korea 21 Project for Medical Science, Seoul, Korea
6Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea
Correspondence: Tae-Hyun Yoo Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. E-mail: yoosy0316@yuhs.ac
*

Chang-Yun Yoon and Misol Lee contributed equally to this work.

Received 2016 April 03; Revised 2016 August 06; Accepted 2016 September 23.

Abstract

Background

Hepatic steatosis measured with controlled attenuation parameter (CAP) using transient elastography predicts metabolic syndrome in the general population. We investigated whether CAP predicted metabolic syndrome in chronic kidney disease patients.

Methods

CAP was measured with transient elastography in 465 predialysis chronic kidney disease patients (mean age, 57.5 years).

Results

The median CAP value was 239 (202–274) dB/m. In 195 (41.9%) patients with metabolic syndrome, diabetes mellitus was more prevalent (105 [53.8%] vs. 71 [26.3%], P < 0.001), with significantly increased urine albumin-to-creatinine ratio (184 [38–706] vs. 56 [16–408] mg/g Cr, P = 0.003), high sensitivity C-reactive protein levels (5.4 [1.4–28.2] vs. 1.7 [0.6–9.9] mg/L, P < 0.001), and CAP (248 [210–302] vs. 226 [196–259] dB/m, P < 0.001). In multiple linear regression analysis, CAP was independently related to body mass index (β = 0.742, P < 0.001), triglyceride levels (β = 2.034, P < 0.001), estimated glomerular filtration rate (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), alanine aminotransferase (β = 0.064, P = 0.029), and total bilirubin (β = −0.881, P = 0.009). In multiple logistic regression analysis, increased CAP was independently associated with increased metabolic syndrome risk (per 10 dB/m increase; odds ratio, 1.093; 95% confidence interval, 1.009–1.183; P = 0.029) even after adjusting for multiple confounding factors.

Conclusion

Increased CAP measured with transient elastography significantly correlated with and could predict increased metabolic syndrome risk in chronic kidney disease patients.

Introduction

Metabolic syndrome (MS), comprising hypertension, hypertriglyceridemia, hyperglycemia, low high-density lipoprotein cholesterol (HDL-C) levels, and central obesity, is closely correlated with insulin resistance, chronic inflammation, and cardiovascular disease development [1]. Several studies reported that MS is associated with chronic kidney disease (CKD) or albuminuria [2,3], and that patients with MS have increased all-cause and cardiovascular mortality in both CKD and the general populations [4]. Regarding the relationship between MS and CKD, several epidemiologic studies demonstrate that hyperglycemia, hypertension, low HDL-C levels, and hypertriglyceridemia were major risk factors for CKD development and progression. However, waist circumference, body mass index (BMI), and obesity, important signs of insulin resistance of MS, are confusing factors, especially in CKD patients.

Obese populations with renal impairment showed reverse epidemiology compared with the general population [5]. This paradox is not explained by traditional pathophysiologic mechanisms; thus, investigation of factors such as sarcopenic obesity [6], waist-to-hip ratio [7], or metabolically healthy obesity [8] is needed. Among these surrogate findings of metabolic derangements, interest in the liver as a phenotype of sarcopenia and central obesity has been increasing in the last decade [9]. Recent observations suggest that fatty liver or steatohepatitis, are a surrogate marker for MS. In addition, non-alcoholic fatty liver disease (NAFLD) is an extremely common liver disease accompanied by metabolic derangements and is considered a hepatic manifestations of MS [10]. NAFLD is strongly associated with insulin resistance caused by low physical activity and increased fat mass [11].

Transient elastography (FibroScan; Echosens, Paris, France) was originally invented for non-invasive detection and assessing liver cirrhosis severity [12]. Transient elastography has recently been used for evaluating liver elasticity and viscosity with ultrasonic signals, known as the controlled attenuation parameter (CAP). Accumulating evidences suggest that CAP could estimate the degree of hepatic steatosis and be a substitute for invasive liver biopsies [13]. Moreover, previous studies showed that CAP is useful in assessing the severity of NAFLD and is closely associated with MS in the general populations [14].

Therefore, this study aimed to elucidate whether CAP measurement using transient elastography has a predictive role in assessing metabolic derangements in CKD patients.

Methods

Ethics statement

The study was carried out in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Yonsei University Health System (YUHS) Clinical Trial Center.

Subjects

All pre-dialysis CKD patients without liver disease who underwent transient elastography at YUHS were initially screened for enrollment between November 2011 and December 2014 in this observational study. Patients under 18 years old were excluded. The exclusion criteria included the presence of hepatitis B surface antigen, hepatitis C virus antibodies, concomitant or previous history of liver cirrhosis, alcoholic hepatitis, alcoholic liver disease, drug induced hepatitis, fulminant hepatitis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma, biliary tract cancer, gallbladder cancer, any cancer with metastasis to the liver, or type 1 hepatorenal syndrome. Patients whose MS parameters were unavailable were also excluded. Finally, 465 CKD patients were analyzed (Fig. 1).

Figure 1

Flow diagram of the study

CKD, chronic kidney disease; IQR, interquartile range; LS, liver stiffness; M, median.

Clinical and biochemical data collection

Demographic and clinical data were collected from the registered database at YUHS. BMI was calculated as weight divided by square of height (kg/m2). Diabetes mellitus and hypertension were defined as previous described [15,16]. CKD stage was defined by the Kidney Disease Improving Global Outcomes 2012 guideline [17], and estimated glomerular filtration rate (eGFR) was calculated by the CKD epidemiology collaboration equation [18]. Biochemical data including urine albumin-to-creatinine ratio (UACR) was analyzed before or after 6 months at the time of transient elastography. Serum total cholesterol, HDL-C, low-density lipoprotein cholesterol, and triglyceride levels were measured by enzymatic colorimetry using an autoanalyzer (Hitachi 7150; Hitachi Ltd, Tokyo, Japan), and high-sensitivity C-reactive protein (hs-CRP) levels were determined by a latex-enhanced immunonephelometric method using a BNII analyzer (Dade Behring, Newark, DE, USA).

Diagnosis of metabolic syndrome

The National Cholesterol Education Program (Adult Treatment Panel [ATP] III) [19] bases the diagnosis of MS on the presence of three or more of the following: 1) systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg; 2) triglyceride levels ≥ 150 mg/dL, 3) HDL-C levels < 40 mg/dL in men or < 50 mg/dL in women; 4) fasting plasma glucose levels ≥ 110 mg/dL; and 5) abdominal obesity. We based abdominal obesity on BMI rather than on waist circumference because of the participants with a BMI ≥ 25 kg/m2 classified centrally obese in accordance with the Western Pacific Region of the World Health Organization (WPRO) criteria [20]. The modified ATP III definition used in this study has been determined to be more accurate than the WPRO criteria for the diagnosis of MS in Asians [21].

Liver stiffness and controlled attenuation parameter measurements

Liver stiffness (LS) and CAP measurements were performed by transient elastography on the right lobe of the liver through the intercostal spaces while patients were lying in the dorsal decubitus position with the right arm in maximal abduction. The final LS result was expressed in kPa and was the median value of 10 measurements performed between 25 and 65 mm depth. Only result with 10 valid shots and an interquartile range divided by median LS ratio < 30% were included [12].

The principle of CAP measurement has been described previously [22]. In brief, the CAP measures reflected ultrasonic attenuations at 3.5 MHz using signals acquired by transient elastography. The final CAP was computed only when the associated LS measurement was valid and using the same signals as the one used to measure LS. Therefore, both LS and CAP were obtained simultaneously and in the same volume of liver parenchyma. The final CAP value was presented by the median of individual CAP values and was expressed in dB/m [14].

Statistical analysis

Continuous variables were expressed as mean ± standard deviation or median (range), while categorical variables were expressed as a number (percentage). Normality of distribution was ascertained with the Kolmogorov-Smirnov test. To compare differences between patients with and without MS, Student’s t-test or the Mann-Whitney U-test were used for continuous variables, and the chi-square test or the Fisher’s exact test were used for categorical variables. Univariate and multiple linear regression analyses were performed to determine significant factors associated with LS and CAP. Regarding variable distribution, UACR, hs-CRP, and LS were used with natural log values for linear regression analysis. The variables with P-values < 0.05 with univariate linear regression analysis were included in multiple linear regression analysis. The independent predictive role of CAP for the presence of MS was confirmed through logistic regression analysis, which included significant variables when comparing baseline characteristics according to the presence of MS and multiple linear regression analysis. We further modified the above logistic regression analyses by using a restricted cubic spline model to illustrate systemic relations between the degree of CAP values and the risk of MS. The statistical significance of the mean CAP across the number of MS components was verified with the Trend test. Statistical analysis was performed with IBM SPSS software for Windows version 23.0 (IBM Corporation, Armonk, NY, USA). P-values < 0.05 were considered significant.

Results

Baseline characteristics according to the presence of metabolic syndrome

The baseline characteristics are shown in Table 1. The mean age of the study population was 57.5 ± 17.0 years, and 225 (48.4%) patients were men. There were 265 (57.0%), 131 (28.2%), 43 (9.2%), 16 (3.4%), and 10 (2.2%) patients with stage 1 to 5 CKD, respectively. The mean eGFR was 87.9 ± 28.3 mL/min/1.73 m2, and the median CAP was 239 dB/m. MS was present in 195 (41.9%) patients. Patients were divided into two groups according to the presence of MS. MS group had more diabetes mellitus (105 [53.8%] vs. 71 [26.3%], P < 0.001), significantly higher UACR (184 [38–706] vs. 56 [16–408] mg/g Cr, P = 0.003), hs-CRP levels (5.4 [1.4–28.2] vs. 1.7 [0.6–9.9] mg/L, P < 0.001), LS (5.6 [4.6–8.6] vs. 4.9 [4.1–7.1] kPa, P = 0.003), and CAP (248 [210–302] vs. 226 [196–259] dB/m, P < 0.001) compared with non-MS group.

Baseline characteristics of subjects

Linear regression analyses performed with liver stiffness or controlled attenuation parameter

Univariate linear regression analysis was performed to investigate the association between clinical and biochemical variables with the value measured with transient elastography (Table 2). Fasting glucose, serum creatinine, log UACR, aspartate aminotransferase (AST), alanine transaminase (ALT), total bilirubin, and log hs-CRP levels were positively correlated with log LS, while cholesterol, HDL-C, and serum albumin levels were negatively correlated with log LS. BMI, diastolic blood pressure, the presence of diabetes mellitus, fasting glucose, cholesterol, log triglyceride, eGFR, serum albumin, and ALT levels were positively correlated with CAP, while age, BUM, and total bilirubin levels were negatively correlated with CAP values.

Univariate linear regression analyses for the association of liver stiffness and controlled attenuation parameter with variables

Multiple linear regression analysis was also performed to clarify the independent demographic and biochemical variables with LS or CAP values in patients with CKD (Table 3). The analysis revealed that log LS was independently associated with log UACR (β = 0.063, P = 0.026) and total bilirubin levels (β = 0.309, P < 0.001), while CAP was independently associated with BMI (β = 0.742, P < 0.001), log triglyceride (β = 2.034, P < 0.001), eGFR (β = 0.316, P = 0.001), serum albumin (β = 1.386, P < 0.001), ALT (β = 0.064, P = 0.029), and total bilirubin levels (β = −0.881, P = 0.009).

Multiple linear regression analyses for the association of liver stiffness and controlled attenuation parameter with variables

Controlled attenuation parameter is an independent risk factor for the presence of metabolic syndrome in patients with chronic kidney disease

Logistic regression analysis was performed to investigate the predictive impact of CAP on the prevalence of MS in CKD patients (Table 4). CAP was significantly associated with the prevalence of MS in a crude model (CAP, 10 dB/m increase; odds ratio [OR], 1.101; 95% confidence interval [CI], 1.060–1.143; P < 0.001; data not shown). In addition, a significant association remained after adjustment for not only liver function-related factors but also traditional risk factors including age, sex, diabetes mellitus, hypertension, total bilirubin levels, serum albumin levels, eGFR, UACR, hs-CRP, and HDL-C levels (CAP, 10 dB/m increase; OR, 1.093; 95% CI, 1.009–1.183; P=0.029). On the other hand, LS did not show a significant correlation with the presence of MS in CKD patients. The association between CAP groups which were divided into five groups, and full-adjusted odds ratio was constructed and described as cubic spline curves in Fig. 2. As shown, the OR is increased from around 3rd group, then the statistical significance is appears around 4th group. In addition, the mean value of CAP linearly increased with the number of MS components, and the trend showed significant statistic power (P for trend < 0.001, Fig. 3).

Controlled attenuation parameter as an independent predictor of metabolic syndrome in patients with chronic kidney disease

Figure 2

A cubic spline curves for the presence of metabolic syndrome according to the degree of CAP values in patients with chronic kidney disease

The models were adjusted for age, gender, history of diabetes mellitus and hypertension, total bilirubin, serum albumin, eGFR, UACR, hs-CRP, and HDL-C. The solid line represents the log odds of metabolic syndrome according to CAP, and the dotted line representes 95% CI.

CAP, controlled attenuation parameter; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; UACR, urine albumin-to-creatinine ratio.

Figure 3

Controlled attenuation parameter according to the number of metabolic syndrome (MS) components

Each bar represents the mean and 95% confidence interval. Controlled attenuation parameter values increased in parallel with the number of metabolic syndrome components (P < 0.001).

CAP, controlled attenuation parameter.

Body mass index and triglyceride levels are the main factors affecting the predictive role of controlled attenuation parameter in diagnosing metabolic syndrome

To investigate the main factors affecting the predictive power of CAP in diagnosing MS, the proportion of diagnosed MS components according to the dichotomized CAP is presented (Fig. 4). High and low CAP groups were generated by the median value of CAP score. Among the five diagnostic criteria of MS, BMI (27.7% vs. 72.3%, P < 0.001) and triglyceride levels (32.5% vs. 67.5%, P < 0.001) were significantly more prevalent in the higher-CAP compared with the lower-CAP group, but fasting plasma glucose levels, HDL-C levels, and systolic blood pressure were not significantly different between groups.

Figure 4

The proportions of metabolic factors which satisfy the criteria of metabolic syndrome (MS) according to the dichotomized CAP

Among the five diagnostic criteria of MS, BMI (27.7% vs. 72.3%, P < 0.001) and TG (32.5% vs. 67.5%, P < 0.001) showed significant higher proportions in the higher CAP group than the lower CAP group, but fasting plasma glucose, HDL-C, and SBP did not show differences between the two groups.

BMI, body mass index; CAP, controlled attenuation parameter; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.

Discussion

In the present study, we found that the CAP value was independently associated with the presence of MS in pre-dialysis CKD patients. The liver and muscles are target organs for insulin action. Recently, the role of the liver in insulin resistance is being investigated; several observational studies suggest that NAFLD is closely associated with insulin resistance and sarcopenia [23]. Hitherto, the underlying mechanisms for an association between NAFLD and sarcopenia are not fully elucidated. Previous studies proposed that hepatic steatosis was strongly correlated with insulin resistance, mitochondrial dysfunction, and consequent muscle breakdown [24]. In particular, several adipokines produced by adipose tissues are reported to be involved in modulating insulin action in metabolic tissues such as the muscles and liver [25]. Furthermore, patients with chronic liver disease or cirrhosis reportedly have lower levels of insulin growth factor-1 and increased levels of various cytokines such as tumor necrosis factor alpha and transforming growth factor beta, which are significantly associated with sarcopenia [26]. In a previous study, sarcopenia was commonly reported in CKD patients and was related to protein-energy wasting, inflammation, and cardiovascular mortality in them [6,27]. In our study, CAP values as a marker for hepatic steatosis were significantly higher in CKD patients with MS in accordance with previous studies performed on patients without kidney abnormalities.

Studies on the association between obesity and metabolic risk factors have shown conflicting results in CKD patients. Although an inverse association between BMI and survival rates is reported in CKD patients including dialysis patients [28,29], several studies show that central obesity assessed through anthropometric measurements is associated with a higher risk of cardiovascular mortality in patients with CKD as well as dialysis patients [30]. These data suggested that metabolic abnormalities affected by visceral adiposity might be an important risk factor for cardiovascular mortality and morbidity. Accumulation of visceral fat leads to increased excretion of pro-inflammatory cytokines that may stimulate aggravation of hepatic steatosis and have a catabolic effect on the skeletal muscles [31]. Since CKD leads to metabolic abnormalities such as impaired glucose and protein metabolism, increased oxidative stress, and systemic inflammation, MS in CKD patients is frequently observed and is also considered a non-traditional risk factor for cardiovascular outcomes. The present study suggested that measurement of hepatic steatosis could help to detect MS in CKD patients.

Transient elastography is a newly invented diagnostic tool that is non-invasive, painless, easy to perform, and has superior reliability for pathologic diagnosis [32]. Because of the unique role of the liver in the regulation of metabolic derangement, the use of transient elastography has been expanded to evaluate NAFLD and MS [9]. CAP is calculated by using the velocity and intensity of reflected ultrasonic signals; it reveals the stiffness, viscosity, and elasticity of the liver; thus, CAP could measure hepatic steatosis.

The CAP score, distinct from the LS score obtained through transient elastography, has been recently established and determined as a reliable method to detect hepatic steatosis [13,14,22]. In addition, a large prospective study revealed that CAP was significantly correlated with traditional metabolic risk factors such as age, sex, and BMI as well as MS itself [14]. One previous study already revealed the usefulness of CAP in CKD patients, showing that hepatic steatosis measured with CAP was significantly correlated with serum creatinine and hs-CRP levels [33]. The present study also demonstrated that LS was closely correlated with liver function parameters such as serum albumin and prothrombin time [12]. CAP was significantly increased in CKD patients with MS, and CAP was independently associated with BMI and triglyceride levels in multiple linear regression analysis. In addition, increased CAP was independently associated with the presence of MS in the CKD population after adjustment for multiple factors, including liver function-related and traditional risk factors. Further analysis indicated that the significant association between CAP and MS in CKD patients is mainly caused by BMI and serum triglyceride levels. Obesity is the most significant single risk factor for the development of hepatic steatosis [34], especially excess central or visceral fat [35]. Based on these observations, CAP using transient elastography can be a useful tool to detect MS and central obesity in CKD patients, consistent with previous studies.

Our study has several limitations. First, the assessment of MS was made only at a single time point, and the present study was performed by using a cross-sectional analysis method. For clarifying the clinical impact of CAP on patients with renal impairment, prospective follow-up studies are necessary. Second, the study patients were relatively skewed to stage 1 or 2 CKD; thus, the application of this result to patients with moderate to severe CKD is limited. Finally, since we did not measure muscle strength or skeletal mass, the association between MS and sarcopenic obesity is unclear. Further confirmatory studies to examine the possible mechanisms of the effect of hepatic steatosis on muscle mass and MS development are warranted.

In conclusion, increased CAP measured with transient elastography was significantly associated with an increased risk of MS in CKD patients. These data suggest that hepatic steatosis measured with CAP could be a novel surrogate marker for MS in CKD patients.

Acknowledgments

We thank the Institute of Gastroenterology, Yonsei University College of Medicine for providing data about transient elastography. This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2014–050098), and by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (H14C2003).

Notes

Conflicts of interest

All authors have no conflicts of interest to declare.

References

1. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595–2600. 2004;10.1210/jc.2004-0372. 15181029.
2. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:2134–2140. 2005;10.1681/ASN.2005010106. 15901764.
3. Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, Takishita S, Iseki K. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res 30:937–943. 2007;10.1291/hypres.30.937. 18049025.
4. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683–689. 2001;10.2337/diacare.24.4.683. 11315831.
5. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63:793–808. 2003;10.1046/j.1523-1755.2003.00803.x. 12631061.
6. Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman ME, Barany P, Stenvinkel P, Lindholm B. Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 86:633–638. 2007;17823427.
7. Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS, Sarnak MJ. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 52:49–57. 2008;10.1053/j.ajkd.2008.04.002. 18514990. 2693892.
8. Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, Yamazaki M, Oda Y, Hasegawa G, Toda H, Nakamura N, Fukui M. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol 10:578–583. 2015;10.2215/CJN.08980914. 25635035. 4386260.
9. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:124–131. 2011;10.1053/j.gastro.2010.09.038.
10. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850. 2001;10.2337/diabetes.50.8.1844. 11473047.
11. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44–52. 2005;10.1002/hep.20734. 15895401.
12. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55:403–408. 2006;10.1136/gut.2005.069153.
13. Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, Ahn SH, Chon CY, Lee HW, Park Y, Han KH. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int 34:102–109. 2014;10.1111/liv.12282.
14. de Lédinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, Merrouche W, Foucher J, Brigitte le B. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 60:1026–1031. 2014;10.1016/j.jhep.2013.12.018. 24378529.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 37(Suppl 1):S81–S90. 2014;10.2337/dc14-S081.
16. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, Mac-Kenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507–520. 2014;10.1001/jama.2013.284427.
17. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830. 2013;10.7326/0003-4819-158-11-201306040-00007. 23732715.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612. 2009;10.7326/0003-4819-150-9-200905050-00006. 19414839. 2763564.
19. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497. 2001;10.1001/jama.285.19.2486. 11368702.
20. Anuurad E, Shiwaku K, Nogi A, Kitajima K, Enkhmaa B, Shimono K, Yamane Y. The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health 45:335–343. 2003;10.1539/joh.45.335. 14676412.
21. Shiwaku K, Nogi A, Kitajima K, Anuurad E, Enkhmaa B, Yamasaki M, Kim JM, Kim IS, Lee SK, Oyunsuren T, Yamane Y. Prevalence of the metabolic syndrome using the modified ATP III definitions for workers in Japan, Korea and Mongolia. J Occup Health 47:126–135. 2005;10.1539/joh.47.126. 15824477.
22. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, Miette V. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36:1825–1835. 2010;10.1016/j.ultrasmedbio.2010.07.005. 20870345.
23. Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 59:1772–1778. 2014;10.1002/hep.26716.
24. Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, Kang ES, Han KH, Lee HC, Cha BS. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). J Hepatol 63:486–493. 2015;10.1016/j.jhep.2015.02.051. 25772036.
25. Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 48:1253–1262. 2007;10.1194/jlr.R700005-JLR200. 17374880. 4303760.
26. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils. Curr Opin Clin Nutr Metab Care 6:79–85. 2003;10.1097/00075197-200301000-00012.
27. Kara E, Sahutoglu T, Ahbap E, Sakaci T, Koc Y, Basturk T, Sevinc M, Akgol C, Unsal A. The predictive value of malnutrition - inflammation score on 1-year mortality in Turkish maintenance hemodialysis patients. Clin Nephrol 86:94–99. 2016;10.5414/CN108799. 27345184.
28. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 46:489–500. 2005;10.1053/j.ajkd.2005.05.020. 16129211.
29. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 16:2386–2394. 2001;10.1093/ndt/16.12.2386. 11733631.
30. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care 15:12–22. 2012;10.1097/MCO.0b013e32834dd297.
31. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2:819–829. 2014;10.1016/S2213-8587(14)70034-8. 24731660. 4156923.
32. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, Yonemitsu K, Higurashi T, Takahashi H, Kobayashi N, Kirikoshi H, Abe Y, Inamori M, Kubota K, Saito S, Tamano M, Hiraishi H, Maeyama S, Yamaguchi N, Togo S, Nakajima A. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 40:371–378. 2008;10.1016/j.dld.2007.10.019.
33. Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res 37:305–310. 2013;10.1159/000350158. 24029696.
34. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 353:1634–1636. 1999;10.1016/S0140-6736(99)00163-4. 10335777.
35. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 18:353–358. 1999;10.1016/S0261-5614(99)80015-6.

Article information Continued

Figure 1

Flow diagram of the study

CKD, chronic kidney disease; IQR, interquartile range; LS, liver stiffness; M, median.

Figure 2

A cubic spline curves for the presence of metabolic syndrome according to the degree of CAP values in patients with chronic kidney disease

The models were adjusted for age, gender, history of diabetes mellitus and hypertension, total bilirubin, serum albumin, eGFR, UACR, hs-CRP, and HDL-C. The solid line represents the log odds of metabolic syndrome according to CAP, and the dotted line representes 95% CI.

CAP, controlled attenuation parameter; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; UACR, urine albumin-to-creatinine ratio.

Figure 3

Controlled attenuation parameter according to the number of metabolic syndrome (MS) components

Each bar represents the mean and 95% confidence interval. Controlled attenuation parameter values increased in parallel with the number of metabolic syndrome components (P < 0.001).

CAP, controlled attenuation parameter.

Figure 4

The proportions of metabolic factors which satisfy the criteria of metabolic syndrome (MS) according to the dichotomized CAP

Among the five diagnostic criteria of MS, BMI (27.7% vs. 72.3%, P < 0.001) and TG (32.5% vs. 67.5%, P < 0.001) showed significant higher proportions in the higher CAP group than the lower CAP group, but fasting plasma glucose, HDL-C, and SBP did not show differences between the two groups.

BMI, body mass index; CAP, controlled attenuation parameter; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglyceride.

Table 1

Baseline characteristics of subjects

Variable Total (n = 465) Non-MS (n = 270, 58.1%) MS (n = 195, 41.9%) P
CAP (dB/m) 239 (202–274) 226 (196–259) 248 (210–302) < 0.001*
Liver stiffness (kPa) 5.3 (4.3–7.6) 4.9 (4.1–7.1) 5.6 (4.6–8.6) 0.003*
Age (yr) 57.5 ± 17.0 56.1 ± 17.9 59.5 ± 15.4 0.036
Male 225 (48.4) 119 (44.1) 106 (54.4) 0.029
BMI (kg/m2) 23.8 ± 3.5 22.8 ± 3.1 25.2 ± 3.5 < 0.001
SBP (mmHg) 128.5 ± 20.2 122.6 ± 18.6 136.6 ± 19.6 < 0.001
DBP (mmHg) 76.6 ± 12.6 73.4 ± 11.5 81.0 ± 12.8 < 0.001
CKD stage 0.008
 Stage 1 265 (57.0) 169 (62.6) 96 (49.2)
 Stage 2 131 (28.2) 70 (25.9) 61 (31.3)
 Stage 3 43 (9.2) 23 (8.5) 20 (10.3)
 Stage 4 16 (3.4) 6 (2.2) 10 (5.1)
 Stage 5 10 (2.2) 2 (0.7) 8 (4.1)
Diabetes mellitus 176 (37.8) 71 (26.3) 105 (53.8) < 0.001
Hypertension 245 (52.7) 120 (44.4) 125 (64.1) < 0.001
Fasting glucose (mg/dL) 118.9 ± 44.0 107.2 ± 35.3 135.2 ± 49.5 < 0.001
Cholesterol (mg/dL) 167.5 ± 48.3 168.5 ± 48.2 166.2 ± 48.6 0.617
Triglyceride (mg/dL) 107 (77–155) 89 (66–119) 155 (103–204) < 0.001*
HDL-C (mg/dL) 45.0 ± 13.5 49.4 ± 13.5 38.2 ± 10.4 < 0.001
LDL-C (mg/dL) 102.7 ± 42.7 104.4 ± 45.0 100.5 ± 39.4 0.365
BUN (mg/dL) 16.4 ± 9.1 15.3 ± 7.7 18.0 ± 10.6 0.003
Creatinine (mg/dL) 1.12 ± 0.93 1.00 ± 0.55 1.28 ± 1.26 0.004
eGFR (mL/min/1.73 m2) 87.9 ± 28.3 91.9 ± 26.5 82.4 ± 29.8 < 0.001
UACR (mg/g Cr) 113 (23–559) 56 (16–408) 184 (38–706) 0.003*
Serum albumin (g/dL) 3.9 ± 0.7 3.9 ± 0.7 3.7 ± 0.7 0.011
AST (U/L) 25 (19–40) 24 (18–37) 27 (20–43) 0.039*
ALT (U/L) 23 (15–42) 21 (13–36) 25 (16–53) 0.002*
Total bilirubin (mg/dL) 0.6 (0.5–0.8) 0.6 (0.5–0.9) 0.6 (0.4–0.8) 0.013*
hs-CRP (mg/L) 2.7 (0.9–17.7) 1.7 (0.6–9.9) 5.4 (1.4–28.2) < 0.001*

Data are presented as median (range), number (%), or mean ± standard deviation.

ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CAP, controlled attenuation parameter; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; MS, metabolic syndrome; SBP, systolic blood pressure; UACR, urine albumin-to-creatinine ratio.

*

Mann-Whitney’s U-test.

Table 2

Univariate linear regression analyses for the association of liver stiffness and controlled attenuation parameter with variables

Variable Liver stiffness* Controlled attenuation parameter


β (95% CI) P β (95% CI) P
Age (per 1 yr) −0.001 (−0.005 to 0.002) 0.437 −0.039 (−0.068 to −0.010) 0.008
Male 0.006 (−0.117 to 0.129) 0.922 0.279 (−0.706 to 1.264) 0.578
Body mass index (per 1 kg/m2) 0.012 (−0.006 to 0.030) 0.180 0.841 (0.720 to 0.961) <0.001
SBP (per 10 mmHg) −0.009 (−0.040 to 0.023) 0.585 0.125 (−0.124 to 0.374) 0.326
DBP (per 10 mmHg) −0.045 (−0.096 to 0.005) 0.077 0.743 (0.349 to 1.138) <0.001
Diabetes mellitus 0.012 (−0.115 to 0.138) 0.856 1.052 (0.041 to 2.062) 0.041
Hypertension 0.096 (−0.026 to 0.219) 0.124 0.294 (−0.695 to 1.283) 0.560
Fasting glucose (per 10 mg/dL) 0.015 (0.001 to 0.029) 0.036 0.011 (−0.101 to 0.124) 0.844
Cholesterol (per 10 mg/dL) −0.016 (−0.029 to −0.003) 0.014 0.185 (0.083 to 0.286) <0.001
Triglyceride (per 1 log)* 0.020 (−0.101 to 0.142) 0.742 3.702 (2.791 to 4.614) <0.001
HDL-C (per 1 mg/dL) −0.006 (−0.011 to −0.001) 0.021 −0.032 (−0.071 to 0.006) 0.099
LDL-C (per 1 mg/dL) −0.001 (−0.002 to 0.001) 0.288 0.011 (−0.001 to 0.023) 0.084
BUN (per 10 mg/dL) 0.063 (−0.004 to 0.130) 0.066 −0.850 (−1.387 to −0.313) 0.002
Creatinine (per 1 mg/dL) 0.089 (0.023 to 0.155) 0.008 −0.477 (−1.009 to 0.054) 0.078
eGFR (per 10 mL/min/1.73 m2) −0.017 (−0.038 to 0.005) 0.132 0.254 (0.081 to 0.427) 0.004
UACR (per 1 log)* 0.084 (0.040 to 0.127) <0.001 −0.221 (−0.585 to 0.142) 0.231
Serum albumin (per 1 g/dL) −0.168 (−0.258 to −0.077) <0.001 2.613 (1.913 to 3.313) <0.001
AST (per 10 U/L) 0.011 (0.003 to 0.020) 0.010 0.022 (−0.049 to 0.092) 0.541
ALT (per 10 U/L) 0.011 (0.002 to 0.020) 0.018 0.091 (0.019 to 0.162) 0.013
Total bilirubin (per 1 mg/dL) 0.223 (0.125 to 0.320) <0.001 −1.033 (−1.828 to −0.238) 0.011
hs-CRP (per 1 log)* 0.177 (0.101 to 0.253) <0.001 −0.485 (−1.073 to 0.104) 0.106

ALT, alanine transaminase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; UACR, urine albumin-to-creatinine ratio.

*

Log transformed;

per 10 dB/m increase.

Table 3

Multiple linear regression analyses for the association of liver stiffness and controlled attenuation parameter with variables

Variable Liver stiffness* Controlled attenuation parameter


β (95% CI) P β (95% CI) P
Age (per 1 yr) 0.023 (−0.007 to 0.052) 0.130
Body mass index (per 1 kg/m2) 0.742 (0.614 to 0.869) <0.001
DBP (per 10 mmHg) 0.041 (−0.295 to 0.378) 0.810
Diabetes mellitus 0.502 (−0.404 to 1.407) 0.277
Fasting glucose (per 10 mg/dL) 0.006 (−0.015 to 0.028) 0.553
Cholesterol (per 10 mg/dL) −0.015 (−0.037 to 0.007) 0.185 0.005 (−0.083 to 0.093) 0.919
Triglyceride (per 1 log)* 2.034 (1.189 to 2.878) <0.001
HDL-C (per 1 mg/dL) −0.005 (−0.014 to 0.005) 0.316
Creatinine (per 1 mg/dL) 0.027 (−0.064 to 0.118) 0.561
eGFR (per 10 mL/min/1.73 m2) 0.316 (0.137 to 0.494) 0.001
UACR (per 1 log)* 0.063 (0.008 to 0.118) 0.026
Serum albumin (per 1 g/dL) −0.115 (−0.287 to 0.056) 0.185 1.386 (0.685 to 2.088) <0.001
AST (per 10 U/L) −0.005 (−0.035 to 0.024) 0.721
ALT (per 10 U/L) 0.007 (−0.019 to 0.032) 0.611 0.064 (0.007 to 0.121) 0.029
Total bilirubin (per 1 mg/dL) 0.309 (0.157 to 0.461) <0.001 −0.881 (−1.536 to −0.226) 0.009
hs-CRP (per 1 log)* 0.030 (−0.104 to 0.165) 0.656

ALT, alanine transaminase; AST, aspartate aminotransferase; CI, confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; UACR, urine albumin-to-creatinine ratio.

*

Log transformed;

per 10 dB/m increase.

Table 4

Controlled attenuation parameter as an independent predictor of metabolic syndrome in patients with chronic kidney disease

Model Liver stiffness, 1 kPa increase CAP, 10 dB/m increase


OR (95% CI) P OR (95% CI) P
Model 1 1.004 (0.982–1.027) 0.696 1.104 (1.062–1.149) <0.001
Model 2 1.003 (0.980–1.026) 0.809 1.132 (1.084–1.182) <0.001
Model 3 0.975 (0.936–1.016) 0.224 1.098 (1.029–1.173) 0.005
Model 4 0.961 (0.910–1.015) 0.155 1.093 (1.009–1.183) 0.029

Model 1: adjusted for age, sex, diabetes mellitus, and hypertension; Model 2: adjusted for Model 1 + total bilirubin and serum albumin; Model 3: adjusted for Model 2 + eGFR, UACR, and hs-CRP; Model 4: adjusted for Model 3 + HDL-C.

CAP, controlled attenuation parameter; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; OR, odds ratio; UACR, urine albumin-to-creatinine ratio.